pembrolizumab,enfortumab vedotin
astellas,merck,seagen
['optima', ' ev ', 'ev302']
agree with very promising &amp; consistent between cohorts a &amp; k. ev alone also consistently active across therapy lines. combo toxicity needs attention, education &amp; optimal multid management! awaiting ev302 p3 trial! #esmo22 
Oncologist, Professor, clinical/translational research, Genitourinary Cancers, bladder, prostate, testis, Univ of Washington, Fred Hutch; views are mine